Joseph Schocken was appointed as Director at OMEROS CORP.
“increased the number of its directors to nine and appointed Joseph Schocken as a director, effective immediately.”
OMEROS CORP — fact timeline
Source-grounded facts extracted from OMEROS CORP's SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
OMEROS CORP reported the three months ended March 31, 2026 results: net income Net income for the first quarter of 2026 was $56.1 million, or $0.78 per share, EPS $0.78 per share.
“On May 13, 2026, Omeros Corporation issued a press release announcing financial results for the three months ended March 31, 2026.”
OMEROS CORP reported fourth quarter and year ended December 31, 2025 results: net income Net income for the fourth quarter of 2025 was $86.5 million, or $1.22 per share, compared to a net loss of $31.4 million, EPS Net income for the fourth quarter of 2025 was $86.5 million, or $1.22 per share, compared to a net loss of $31.4 million.
“Omeros Corporation Reports Fourth Quarter and Year-End 2025 Financial Results – Conference Call Today at 4:30 p.m. ET”
OMEROS CORP entered into Asset Purchase Agreement with Novo Nordisk valued at Upfront cash payment of $240 million, plus up to $510 million in development/approval milestones and (effective 2025-12-01).
“the closing of the Transaction (the “Closing”), Omeros received an upfront cash payment of $240.0 million, approximately $72.6 million of which was used to repay the Credit Agreement as described in Item 1.02 above. In addition, Omeros can receive (i) up to a total of $510 million in one-time milestone payments upon the first achievement by Novo Nordisk or its affiliates or sublicensees of each of the development and approval milestone events as set forth in the Agreement and (ii) up to $1.3 billion in one-time milestone payments upon the first achievement by Novo Nordisk or its affiliates or sublicensees of certain sales-based milestone events as set forth in the Agreement. The upfront cash received at closing and the potential milestone payments represent a total of $2.1 billion.”
OMEROS CORP completed a disposition involving Novo Nordisk Health Care AG for upfront cash payment of $240.0 million at closing, plus potential milestone payments up to $1.81 billion (development and sales-based milestones) and tiered roy (closed 2025-11-25).
“development and commercialization activities of both companies (the “Transaction”). At the closing of the Transaction (the “Closing”), Omeros received an upfront cash payment of $240.0 million, approximately $72.6 million of which was used to repay the Credit Agreement as described in Item 1.02 above. In addition, Omeros can receive (i) up to a total of $510 million in”
OMEROS CORP incurred convertible notes of $70.8 million aggregate principal amount with Computershare Trust Company, National Association, as trustee at 9.50% per annum maturing June 15, 2029.
“On May 14, 2025, Omeros Corporation (the “Company”) completed the private exchange (the “Exchange”) of approximately $70.8 million aggregate principal amount of its outstanding Convertible Senior Notes due 2026 (the “2026 Notes”) on a one-for-one basis for newly issued Convertible Senior Notes due 2029 (the “New Notes”).”
David J. Borges was appointed as Vice President, Finance, Chief Accounting Officer and Treasurer at OMEROS CORP.
“On June 10, 2024, the Company’s Board of Directors appointed David J. Borges as the Company’s Vice President, Finance, Chief Accounting Officer and Treasurer, effective June 30, 2024 (the “Effective Date”), and designated him as the Company’s principal financial officer and principal accounting officer as of the Effective Date.”
Michael A. Jacobsen retired as Vice President, Finance, Chief Accounting Officer and Treasurer at OMEROS CORP.
“On June 10, 2024, Michael A. Jacobsen informed the Board of Directors of Omeros Corporation (“Omeros” or the “Company”) of his intention to retire from his positions as the Company’s Vice President, Finance, Chief Accounting Officer and Treasurer, effective June 30, 2024.”
OMEROS CORP reported the first quarter ended March 31, 2024 results: net income Net loss for the first quarter of 2024 was $37.2 million, or $0.63 per share, EPS $0.63 per share.
“Omeros Corporation Reports First Quarter 2024 Financial Results”
OMEROS CORP reported the fourth quarter and year ended December 31, 2023 results: net income Net loss for the fourth quarter of 2023 was $9.1 million, or $0.15 per share, EPS net loss of $117.8 million, or $1.88 per share.
“Omeros Corporation (Nasdaq: OMER), a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market and orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders, today announced recent highlights and developments as well as financial results for the fourth quarter and year ended December 31, 2023, which include: ● Net loss for the fourth quarter of 2023 was $9.1 million, or $0.15 per share, compared to a net loss of $37.8 million, or $0.60 per share for the third quarter of 2023. Net loss from continuing operations was $39.3 million for the 2023 fourth quarter compared to $51.7 million for the prior quarter. ● For the year ended December 31, 2023, net loss was $117.8 million, or $1.88 per share, compared to net income of $47.4 million, or $0.76 per share, in the prior year.”
OMEROS CORP reported nine months ended September 30, 2023 results: net income net loss was $108.8 million, or $1.73 per share, EPS $1.73 per share.
“For the nine months ended September 30, 2023, our net loss was $108.8 million, or $1.73 per share, compared to a net loss of $81.3 million, or $1.30 per share, in the prior year period.”
OMEROS CORP reported third quarter ended September 30, 2023 results: net income Net loss was $37.8 million for the quarter ended September 30, 2023, or $0.60 per share, EPS $0.60 per share.
“Net loss was $37.8 million for the quarter ended September 30, 2023, or $0.60 per share, compared to a net loss in the prior year quarter of $17.5 million, or $0.28 per share.”
OMEROS CORP reported six months ended June 30, 2023 results: net income For the six months ended June 30, 2023 our net loss was $71.0 million, or $1.13 per share.
“For the six months ended June 30, 2023 our net loss was $71.0 million, or $1.13 per share”
OMEROS CORP reported second quarter ended June 30, 2023 results: net income Net loss was $37.3 million in the quarter ended June 30, 2023, or $0.59 per share.
“Net loss was $37.3 million in the quarter ended June 30, 2023, or $0.59 per share”
OMEROS CORP shareholders approved Ratification of Ernst & Young LLP as independent registered public accounting firm.
“Shareholders ratified the appointment of Ernst & Young LLP as Omeros' independent registered public accounting firm”
OMEROS CORP shareholders approved Amendment to Omeros Corporation 2017 Omnibus Incentive Compensation Plan to increase authorized shares.
“Shareholders approved an amendment to the Omeros Corporation 2017 Omnibus Incentive Compensation Plan to increase the number of authorized shares”
OMEROS CORP shareholders approved Advisory vote on the frequency of future advisory votes on executive compensation.
“A majority of shareholders voted for 1 Year on an advisory vote on the frequency of future advisory votes on executive compensation”
OMEROS CORP shareholders approved Advisory resolution regarding the compensation of Omeros' named executive officers.
“Shareholders approved an advisory resolution regarding the compensation of Omeros' named executive officers”
OMEROS CORP shareholders approved Election of Class II directors.
“The following individuals were elected to serve as directors by the vote set forth below.”
Diana T. Perkinson was appointed as director at OMEROS CORP.
“increased the number of its directors to nine and appointed Diana T. Perkinson, M.D. as a director, effective immediately.”
OMEROS CORP reported the first quarter ended March 31, 2023 results: net income Net loss was $33.7 million in the first quarter of 2023, or $0.54 per share, EPS $0.54 per share.
“Net loss was $33.7 million in the first quarter of 2023, or $0.54 per share”
OMEROS CORP reported the year ended December 31, 2022 results: net income $47.4 million, EPS $0.76 per share.
“For the year ended December 31, 2022, net income was $47.4 million, or $0.76 per share.”
OMEROS CORP reported the fourth quarter ended December 31, 2022 results: net income $128.7 million, EPS $2.05 per share.
“Net income in the fourth quarter of 2022 was $128.7 million, or $2.05 per share, compared to a net loss in the third quarter of 2022 of $17.5 million, or $0.28 per share;”
OMEROS CORP reported financial results for the year ended December 31, 2022.
“U.S. net sales of OMIDRIA in 2022 totaled $131 million.”
OMEROS CORP reported financial results for three and nine months ended September 30, 2022.
“On November 9, 2022, Omeros Corporation issued a press release announcing financial results for the three and nine months ended September 30, 2022.”
Ray Aspiri retired as Director at OMEROS CORP.
“Ray Aspiri has retired from the board of directors of Omeros Corporation (the “Company”).”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.